Zoeken

Zorgportalen

Plan uw route

Contact

Telefoonnummer
088 75 555 55


Contactgegevens

Vragen, klachten en complimenten

Lees meer

Magazine Uniek

Lees meer

prof.dr. J.W.J. Lammers

prof.dr.  J.W.J.  LammersFunctie: Afdelingshoofd
Specialisme: Longziekten
Afdeling: Afdeling Longziekten
Divisies: Hart & Longen

Contact

E-mail: j.w.j.lammers@umcutrecht.nl
Telefoon: (+31) 88 755 6180

Biografie

Geboortedatum: 13-06-1953
Geboorteplaats: Nijmegen
Datum promotie: 18-04-1986
Titel proefschrift: Beta-adrenoceptor blockadeand stimulation in obstructive lung disease
Datum benoeming: 01-01-1992
Korte biografie:

1971 diploma gymnasium-ß (St. Canisius College, Nijmegen), aanvang studie geneeskunde Katholieke Universiteit Nijmegen

1974 research-stage Department of Physiology, University of Pennsylvania, Philadelphia, V.S.

1979 artsexamen KU Nijmegen

1979-1981 agio interne geneeskunde St. Radboudziekenhuis Nijmegen

1981-1984 opleiding tot longarts Universitair Long Centrum Nijmegen

18-04-1986 Promotie tot doctor in de geneeskunde (KUNijmegen ophet proefschrift getiteld: "Beta-adrenoceptor blockadeand stimulation in obstructive lung disease"

1987 Onderzoeker Department of Thoracic Medicine, Brompton Hospital, Londen, Engeland

1984-1992 Staflid-longarts Universitair Long Centrum Nijmegen

Vanaf 1.1.1992 - heden Hoogleraar longziekten Universiteit Utrecht, tevens hoofd van de afdeling Longziekten van het Universitair Medisch Centrum Utrecht

 

Overige functies:

1993-2001 Medisch Manager van het Hart Long Instituut van het AZU

2001- 2004 Tevens Directeur Onderwijs en Onderzoek, Hart Long Centrum Utrecht

2003-2005 Voorzitter Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT)

Vanaf 2004 Manager Medische Zaken Divisie Hart & Longen UMCUtrecht


Onderzoek

Beschrijving Onderzoek:

The main focus of the Department of Respiratory Medicine is “Chronic Inflammatory Pulmonary Diseases”.

Mission statement: To improve our knowledge of the pathogenesis of inflammatory (lung)diseases such as allergic asthma, COPD, interstitial lung diseases, chronic rejection after lung transplantation and cystic fibrosis with resultant improvements in the monitoring and the treatment of these diseases. Furthermore, to contribute in drug development and targeting in chronic inflammatory diseases.

 

Main lines of own research: Asthma and COPD.

 

This line of research is focused on the chronic innate immune response that plays an important role in chronic inflammatory respiratory diseases. The line is organized around both a fundamental approach and a translational approach. The fundamental line is focused on those activation signals for inflammatory cells that are also found in vivo. This focus is chosen because the chronic innate immune response is an important determinant in the pathogenesis of COPD and is also important in asthma, especially in difficult-to-treat asthmatics that constitute around 15% of all asthma patients.

The research lines are organized to gain more insight into the underlying mechanisms of the diseases involved and to develop strategies for novel therapy and diagnostics.

In collaboration with other departments outside the UMC Utrecht, but mainly within the ABC cluster, the department participates in (Pharmaco)epidemiological studies aimed at elucidating use and possible side effects ofdrugs for asthma and COPD.

At a national level, the TiPharma initiative has funded two large COPD studies, collaborations between our department and the UMCG and the AZM together with different industrial partners. The aim of this collaboration is to elucidate fundamental aspects of the local and systemic inflammation in COPD.

 

The pulmonary function laboratory has started a research program into early diagnosis of mild COPD to stabilize the disease in that mild stage and prevent irreversible deterioration. The studies performed are aimed to establish 1]the best combination of pulmonary function tests to separate asthma from COPD; 2] the use of carbon monoxide and nitric oxide diffusion capacity to diagnose mild emphysema, 3] the use of exhaled volatile organic compounds to diagnose mild emphysema and 4] the value of classical pulmonary function testing to diagnose mild emphysema.

 

Within the large Nelson screening study on early detection of lung cancer, the department collaborates with the Departments of Radiology of the UMCUtrecht and several departments in the UMCGroningen to detect early emphysema and to investigate different underlying mechanisms. Recently the department has been granted a large funding from the EU (FP 7:COPACETIC) to study the genetic susceptibility to develop COPD.


Key Publications:
  • Esposito-Festen JE, Zanen P, Tiddens HA, Lammers JW Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size.. BrJ Clin Pharmacol. 2007 Sep;64(3):328-34.
  • Luijk B, van den Berge M, Kerstjens HA, Postma DS, Cass L, Sabin A,Lammers JW Effect of an inhaled adenosine A2A agonist on the allergeninduced late asthmatic response.. Allergy. 2008 Jan;63(1):75-80.
  • de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J. 2005 May;25(5):879-84.
  • Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JW Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J. 2004 Apr;23(4):559-64.
  • Gerrits CM, Herings RM, Leufkens HG, Lammers JW N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003 May;21(5):795-8.

Nevenfuncties:
  • Manager Medische Zaken/ voorzitter Managementteam Divisie Hart & Longen, UMC Utrecht
  • Hoofd afdeling Longziekten UMC Utrecht
  • Voorzitter Sectie School voor Longziekten, Nederlandse Vereniging van artsen voor Longziekten en Tuberculose


Specialismen